
Iridescent Bio is a cutting-edge platform that combines physics- and chemistry-based predictive modeling with rigorous analytics to enhance antibody development. By providing deep, quality data on binding affinity, target specificity, and aggregation risks, the platform empowers researchers to make informed decisions in their R&D pipelines. With the ability to generate around 100,000 data points per antibody in just one hour, Iridescent Bio positions itself as a vital resource for biopharma companies looking to accelerate the development of new therapies. The company's unique approach leverages cloud computing and AI, making it a leader in the biopharmaceutical space.

Iridescent Bio is a cutting-edge platform that combines physics- and chemistry-based predictive modeling with rigorous analytics to enhance antibody development. By providing deep, quality data on binding affinity, target specificity, and aggregation risks, the platform empowers researchers to make informed decisions in their R&D pipelines. With the ability to generate around 100,000 data points per antibody in just one hour, Iridescent Bio positions itself as a vital resource for biopharma companies looking to accelerate the development of new therapies. The company's unique approach leverages cloud computing and AI, making it a leader in the biopharmaceutical space.
Sector: Biotechnology (protein/antibody modeling)
Founded: 2023
Location (reported): Leiden, Netherlands
Early investor: UNIIQ (Dec 2023)
Data throughput: ~100,000 data points per antibody (per hour)
Antibody and protein design/analysis—improving selection, optimization, and risk assessment in therapeutic discovery
2023
Biotechnology
350,000 USD
Reported early VC investment; Dealroom listing
“UNIIQ participation in early VC round”